Grayscale Bitcoin Premium Income ETF(BPI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BPI Grayscale Bitcoin Premium Income ETF

未开盘 01-22 16:00:00 EST

30.71

-0.21

-0.69%

盘后30.46

-0.25-0.82%

16:10 EST

最高30.71	最低30.46	成交量687.00
今开30.63	昨收30.93	日振幅0.82%
总市值399.27万	流通市值399.27万	总股本13.00万
成交额2.10万	换手率0.53%	流通股本13.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BPI","market":"US","secType":"STK","nameCN":"Grayscale Bitcoin Premium Income ETF","latestPrice":30.713,"timestamp":1769115600000,"preClose":30.9277,"halted":0,"volume":687,"hourTrading":{"tag":"盘后","latestPrice":30.4601,"preClose":30.713,"latestTime":"16:10 EST","volume":6,"amount":184.278,"timestamp":1769116204453,"change":-0.2529,"changeRate":-0.008234,"amplitude":0},"delay":0,"changeRate":-0.006941996980053497,"floatShares":130000,"shares":130000,"eps":0,"marketStatus":"未开盘","change":-0.2147,"latestTime":"01-22 16:00:00 EST","open":30.63,"high":30.713,"low":30.46,"amount":20971.254141,"amplitude":0.00818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1769158800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1239768000000,"exchange":"ARCA","adjPreClose":30.9277,"sharesOutstanding":130000,"nav":30.72,"aum":3993600,"dividendRate":0.200283,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.4601,"preClose":30.713,"latestTime":"16:10 EST","volume":6,"amount":184.278,"timestamp":1769116204453,"change":-0.2529,"changeRate":-0.008234,"amplitude":0},"volumeRatio":0.293816},"requestUrl":"/m/hq/s/BPI/wiki","defaultTab":"wiki","newsList":[{"id":"2581737039","title":"贝达药业：BPI-572270是一款分子胶抑制剂，目前该项目正推进提交临床研究申请（IND）准备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2581737039","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581737039?lang=zh_cn&edition=full","pubTime":"2025-11-06 11:41","pubTimestamp":1762400460,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司的分子胶和降解剂项目何时可以申报临床？贝达药业（300558.SZ）11月6日在投资者互动平台表示，BPI-572270是一款分子胶抑制剂，目前该项目正在推进提交临床研究申请（IND）的准备工作。CFT8919片是一种具有口服生物利用度的变构 BiDAC 降解剂，CFT8919项目目前在临床Ⅰ期研究中。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwmrcc5817416.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwmrcc5817416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BPI","BK0060","300558","91287"],"gpt_icon":0},{"id":"2564326682","title":"香蕉派推BPI-F5单板计算机：全志T527芯片、双千兆网口","url":"https://stock-news.laohu8.com/highlight/detail?id=2564326682","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564326682?lang=zh_cn&edition=full","pubTime":"2025-09-04 13:40","pubTimestamp":1756964408,"startTime":"0","endTime":"0","summary":"IT之家 9 月 4 日消息，科技媒体 Notebook Check 昨日 发布博文，报道称香蕉派发布全新单板计算机 BPI-F5，搭载全志 T527 八核 Cortex-A55 处理器，配有 2 个千兆网口，官方暂未公布产品售价。BPI-F5 核心采用全志 T527 系统级芯片，内置八核 Cortex-A55 CPU，配备 Mali-G57 MC1 GPU，支持 Vulkan 1.1-1.3、OpenGL ES 3.2 等图形标准。IT之家附上接口图片如下：网络功能同样全面，为满足高速数据传输和多设备互联需求，该单板计算机提供双千兆以太网接口、WiFi 6 无线连接及蓝牙 5.3。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8mNBc71G5ia","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["159813","159998","BPI"],"gpt_icon":0},{"id":"2307220419","title":"贝达药业(300558.SZ)：BPI-460372片临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2307220419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2307220419?lang=zh_cn&edition=full","pubTime":"2023-01-30 19:39","pubTimestamp":1675078780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，公司控股子公司Xcovery Holdings, Inc.(“Xcovery”)收到美国食品药品监督管理局(“美国FDA”)通知，Xcovery申报的BPI-460372片药品临床试验申请已获得美国FDA批准，相关适应症为拟用于晚期实体瘤。据悉，BPI-460372是由公司自主研发的靶向Hippo信号通路的新分子实体化合物，属于新型强效转录增强因子TEAD分子抑制剂。拟用于晚期实体瘤患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/868287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1141","BK0060","BPI","300558","BK0239","03347","BK1583"],"gpt_icon":0},{"id":"2303987579","title":"贝达药业(300558.SZ)：BPI-472372片药品临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2303987579","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2303987579?lang=zh_cn&edition=full","pubTime":"2023-01-13 16:00","pubTimestamp":1673596809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 发布公告，公司于今日收到国家药品监督管理局签发的《受理通知书》，公司申报的BPI-472372片药品临床试验申请已获得NMPA受理。BPI-472372临床前研究展现出优秀的体外及体内活性、药代动力学性质及良好的安全性。截至公告披露日，全球尚无CD73小分子抑制剂上市，BPI-472372属于“境内外均未上市的创新药”，其注册分类为化学药品1类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/861619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BPI","BK0239","BK1583","300558","BK1576","BK0060","BK1141","03347"],"gpt_icon":0},{"id":"2302863487","title":"贝达药业(300558.SZ)：“BPI-452080片”获得临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2302863487","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2302863487?lang=zh_cn&edition=full","pubTime":"2023-01-12 16:59","pubTimestamp":1673513972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，今日，公司收到国家药品监督管理局(以下简称“NMPA”)签发的《药物临床试验批准通知书》(通知书编号：2023LP00075、2023LP00076)，公司申报的BPI-452080片药物临床试验(以下简称“该临床试验”)已获得NMPA批准开展。据悉，BPI-452080是由公司自主研发的拥有完全自主知识产权的新分子实体化合物，是一种创新、口服的小分子HIF-2α(低氧诱导因子 2α，Hypoxia inducible factor-2α)抑制剂，拟用于晚期恶性实体瘤患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/861042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BPI","BK1583","BK0239","300558","BK1141","03347","BK0060"],"gpt_icon":0},{"id":"2300444590","title":"贝达药业(300558.SZ)：BPI-460372片开展晚期实体瘤临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2300444590","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2300444590?lang=zh_cn&edition=full","pubTime":"2023-01-04 17:40","pubTimestamp":1672825220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 发布公告，公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，公司申报的BPI-460372片药品临床试验已获得NMPA批准开展。本品拟用于晚期实体瘤患者的治疗。临床前数据显示，BPI-460372可以特异性靶向Hippo信号通路下游的细胞核内转录因子TEAD，抑制下游基因的转录和翻译，从而抑制肿瘤细胞的增殖、生存、分化和迁移。BPI460372凭借其独特的作用机制，有望解决未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/857087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558","BK0060","BK1141","BK1576","BK0239","03347","BK1583","BPI"],"gpt_icon":0},{"id":"2280574526","title":"贝达药业(300558.SZ)：BPI-452080片药品临床试验申请获受理 拟用于治疗晚期实体瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2280574526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2280574526?lang=zh_cn&edition=full","pubTime":"2022-11-04 17:13","pubTimestamp":1667553194,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)公告，公司申报的BPI-452080片药品临床试验申请已获得国家药品监督管理局受理，据悉，BPI-452080是一种创新、口服的小分子HIF-2α抑制剂，拟用于晚期实体瘤患者的治疗。临床前数据显示，BPI-452080能够特异性阻断HIF-2α与HIF-1β异二聚，抑制下游基因的转录和翻译，从而抑制肿瘤血管生成、细胞增殖、生存和转移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/824072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BPI","03347","BK1141","BK1576","300558","BK0239","BK1583","BK0060"],"gpt_icon":0},{"id":"2276265469","title":"贝达药业(300558.SZ)：BPI-460372临床试验申请获受理 拟用于治疗晚期实体瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2276265469","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2276265469?lang=zh_cn&edition=full","pubTime":"2022-10-20 17:24","pubTimestamp":1666257841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 公告，公司申报的BPI-460372片药品临床试验申请已获得国家药品监督管理局受理。据悉，BPI-460372是由公司自主研发的靶向Hippo信号通路的新分子实体化合物，属于新型强效转录增强因子TEAD小分子抑制剂。拟用于晚期实体瘤患者的治疗。BPI460372凭借其独特的作用机制，有望解决未被满足的临床需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/808819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BPI","BK0060","BK1583","300558","BK1576","BK1141","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bridgepointeducation.com","stockEarnings":[{"period":"1week","weight":-0.0575},{"period":"1month","weight":0.0082},{"period":"3month","weight":-0.217},{"period":"6month","weight":-0.2882},{"period":"1year","weight":1.925},{"period":"ytd","weight":0.0191}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zovio Inc于1999年5月在特拉华州成立，当时的名称为TeleUniversity公司，并于2004年2月更名为Bridgepoint教育公司。该公司是高等教育服务提供商。该公司也专注于开发创新型新技术，以提高学生的学习方式，如通过Waypoint Outcomes，Constellation和各院校移动学习平台的研发。教学机构的在线平台旨在为客户提供优质的教育经验，同时提供许多学生需要的灵活性和便利性，特别是在职人士。教学机构致力于为学生提供高品质的教育经验。教育机构有一个全面的课程开发过程，并雇用有显著的学术和实践经验的合格教员。该公司的收入主要包括学费，技术费和其他杂费，并扣除奖学金和退款。","exchange":"ARCA","name":"Grayscale Bitcoin Premium Income ETF","nameEN":"Grayscale Bitcoin Premium Income ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Grayscale Bitcoin Premium Income ETF(BPI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Grayscale Bitcoin Premium Income ETF(BPI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Grayscale Bitcoin Premium Income ETF,BPI,Grayscale Bitcoin Premium Income ETF股票,Grayscale Bitcoin Premium Income ETF股票老虎,Grayscale Bitcoin Premium Income ETF股票老虎国际,Grayscale Bitcoin Premium Income ETF行情,Grayscale Bitcoin Premium Income ETF股票行情,Grayscale Bitcoin Premium Income ETF股价,Grayscale Bitcoin Premium Income ETF股市,Grayscale Bitcoin Premium Income ETF股票价格,Grayscale Bitcoin Premium Income ETF股票交易,Grayscale Bitcoin Premium Income ETF股票购买,Grayscale Bitcoin Premium Income ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Grayscale Bitcoin Premium Income ETF(BPI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Grayscale Bitcoin Premium Income ETF(BPI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}